ArticleJournal of managed care & specialty pharmacy2015

Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.

Pranav K Gandhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.